Updates on HER2-Directed ADCs Across Solid Tumors : Episode 18

Opinion

Video

August 29, 2024

The Future for HER2-Directed ADCs

Author(s):

Ronan J. Kelly, MD, MBA

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

EP: 1.Assessing HER2 Status Across Tumor Types

EP: 2.ADCs Targeting HER2+ Breast Cancer

EP: 3.ADCs Targeting HER2+ Gynecologic Cancers

EP: 4.Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

EP: 5.ADCs Targeting GI Cancers

EP: 6.ADCs Targeting HER2+ Lung Cancer

EP: 7.Impact of ADCs on Brain Metastases

EP: 8.ADCs Targeting HER2+ GU Cancers

EP: 9.Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

EP: 10.The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

EP: 11.Managing ILD and Pneumonitis Risk From ADCs

EP: 12.Managing Toxicities in Short- and Long-Term Treatment with ADCs

EP: 13.Managing Hematologic AEs Associated with ADC Treatments

EP: 14.Management of Emetogenicity of Antibody-Drug Conjugates

EP: 15.ADC Sequencing

EP: 16.Emerging ADCs in Development

EP: 17.Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

EP: 18.The Future for HER2-Directed ADCs

EP: 19.Key Takeaways and Closing Thoughts on ADCs

Related Videos

Nancy U. Lin, MD, discusses the safety data from DESTINY-Breast12 with T-DXd for HER2+ advanced/metastatic breast cancer with or without brain metastases.

Daniel DeAngelo, MD, PhD, discusses how the shift away from chemotherapy has affected the management of chronic lymphocytic leukemia.

2 KOLs are featured in this series.

5 KOLs are featured in this series.

5 KOLs are featured in this series.

5 KOLs are featured in this series.

Related Content

Natural Killer Cells in Ovarian Cancer | Image Credit: © Dr_Microbe - stock.adobe.com

November 18th 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Matthew Vander Heiden, MD, PhD

November 1st 2024

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

Narjust Florez, MD

September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute

October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

David C. Fisher, MD

October 26th 2024

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma

Related Content

Natural Killer Cells in Ovarian Cancer | Image Credit: © Dr_Microbe - stock.adobe.com

November 18th 2024

First Clinical Trial of “Memory Like” Natural Killer Cells in Ovarian Cancer Opens at Dana-Farber

OncLive On Air

September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Matthew Vander Heiden, MD, PhD

November 1st 2024

Two Dana-Farber Cancer Institute Faculty Members Elected to the National Academy of Medicine

Narjust Florez, MD

September 5th 2024

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Daniel DeAngelo MD, PhD, of Dana-Farber Cancer Institute

October 28th 2024

JAK Inhibitors Remain the Gold Standard in Myelofibrosis

David C. Fisher, MD

October 26th 2024

Bispecific Antibodies, Novel Combinations Highlight Continued Treatment Evolution in Follicular Lymphoma

Latest Conference Coverage

Dr Caimi on Early Data for LMY-920 in R/R B-Cell NHL

Navigating a “Sea Change” in Frontline Urothelial Carcinoma Treatment

Dr Scalici on Data for IMNN-001 Plus SOC Chemotherapy in Advanced Ovarian Cancer

Dr Lin on the Safety of NKTR-255 in Enhancing Immune Recovery Post-Chemoradiation in Locally Advanced NSCLC

View More Latest Conference Coverage

Editorial Board

MJH Life Sciences brands

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.